Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in Adults with Type 1 Diabetes

Trial Profile

A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in Adults with Type 1 Diabetes

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Nov 2018

At a glance

  • Drugs Insulin lispro (Primary) ; Insulin degludec; Insulin glargine
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms PRONTO-T1D
  • Sponsors Eli Lilly; Eli Lilly Japan
  • Most Recent Events

    • 19 Nov 2018 Planned End Date changed from 21 Aug 2019 to 5 Sep 2019.
    • 02 Oct 2018 According to an Eli Lilly media release, detailed results from PRONTO-T1D and PRONTO-T2D will be presented in 2019.
    • 02 Oct 2018 According to an Eli Lilly media release, primary endpoint (Change from Baseline in Hemoglobin A1c (HbA1c)) has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top